Induction Chemo-radiation (50Gy) Followed by Surgery for Stage IIIA-N2 Non-small Cell Lung Cancer.
CONCLUSIONS: Induction chemotherapy with concurrent radiotherapy (50 Gy) followed by surgery was a feasible and promising treatment option for resectable c-stage IIIA-N2 NSCLC. PMID: 29890150 [PubMed - as supplied by publisher]
ConclusionsGenerally, superior vena cava syndrome is the result of extrinsic compression of the superior vena cava by tumor. Our patient ’s case represents the development of superior vena cava syndrome after an excellent response of tumor with near-complete tumor response. We suspect chemoradiation therapy as a potential etiology for the precipitation of the superior vena cava syndrome, which is currently not well reported in the medical literature.
ConclusionsAs treatment options evolve, this study provides real-world treatment patterns that suggest concordance with NCCN guidelines and confirm the remaining need to understand sequencing of therapies and related outcomes.FundingEli Lilly and Company.
Publication date: Available online 17 October 2018Source: Respiratory Medicine Case ReportsAuthor(s): Saad Habib, Lazer Ezriel Leifer, Mohammed Azam, Abdul Hasan Siddiqui, Kartikeya Rajdev, Michel ChalhoubAbstractGiant Cell Carcinoma of the lung, a subtype of Sarcomatoid lung cancer is a poorly differentiated Non-Small-Cell Lung Cancer. GCCL has exceptionally aggressive characteristics, and its prognosis is much poorer than any other NSCLCs. Herein, we present a rare case of Giant Cell Carcinoma of lung treated successfully with surgical resection and adjuvant vinorelbine and cisplatin.A 48-year-old African American man wi...
ConclusionsOur results suggest that rs10414193A>G may be useful for the prediction of clinical outcomes of chemotherapy in advanced NSCLC.
CONCLUSION: PD-L1 expression and the presence of CD8+ TILs could predict neither the patients' response to chemotherapy or MWA nor survival in advanced NSCLC patients treated with MWA plus chemotherapy. PMID: 30307348 [PubMed - as supplied by publisher]
Conclusion Selumetinib at a dose of 75 mg b.i.d continuously can be safely combined with paclitaxel and carboplatin or pemetrexed and cisplatin in patients with advanced or metastatic NSCLC. This trial provided the dose for the regimens used in a randomized phase II trial in NSCLC (CCTG IND.219).
CONCLUSION: Personalized dose-escalation in inoperable NSCLC patients results in higher acute and late toxicity compared to conventional chemoradiotherapy. The toxicity, however, was within the boundaries of the pre-defined stopping rules. PMID: 30327236 [PubMed - as supplied by publisher]
The number of elderly people with advanced lung cancer is increasing globally owing to the aging population and advances in cancer therapy . More than 50% of patients diagnosed with lung cancer are aged>65 years, which is the lower limit for defining “elderly” in epidemiologic researches . Non-small-cell lung cancer (NSCLC) accounts for 85% of all cases of lung cancer among both the elderly  and the adults. Although platinum-combination regimens including newer agents are the standard first-line chemotherapy for most patients with adva nced NSCLC, their use in elderly patients remains controversial .
The majority of inoperable non-small cell lung cancer (NSCLC) patients have high loco-regional progression rates of approximately 30% at two years after treatment with concurrent chemo-radiotherapy (cCRT) . Standard chemo-radiotherapy for patients with a good performance status consists of at least 60 Gy in 6 weeks combined with cis- or carboplatin-based chemotherapy delivered concurrently . A reduction of the overall treatment time (OTT) through the delivery of hypofractionated radiotherapy schedules, e.g.